Lipitor.com gets Bad Ad slap for cross-promotion sans risk info

Share this article:
Pfizer's Lipitor website touted the efficacy of Caduet, Chantix and Norvasc but failed to balance those claims with risk info for the drugs, according to an “untitled letter” from FDA's Division of Drug Marketing, Advertising and Communication (DDMAC).

Acting on a complaint made through the agency's Bad Ad program, which encourages physicians and the public to report sketchy claims made in drug advertising, the FDA asked the company to cut it out. At issue in the August 31 letter was the “Online Resources” section of Lipitor.com, which listed, under the headline “Medicines That May Treat Heart Disease Risk Factors,” the three Pfizer drugs. Caduet is a combo drug pairing atorvastatin (Lipitor), for high cholesterol, with calcium channel blocker amlodipine (Norvasc) for hypertension; and Norvasc in standalone form. Chantix, the letter noted, carries a “Boxed Warning” on dangerous neuropsychiatric side effects.

“By omitting the most serious and frequently occurring risks associated with Caduet, Chantix and Norvasc, the webpagemisleadingly suggests that these drugs are safer than have been demonstrated,” said the letter, which noted that while the company provided links to the product sites, “this is insufficient to mitigate the misleading omission of risk information.”  
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...